Access to the drug INGREZZA is now contingent on coverage through the Medicare system.
3 reports, 2 independent
Updated Jul 31
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Access to the drug INGREZZA is now contingent on coverage through the Medicare system.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Medicare coverage affects patient segments, while acquisitions broaden company portfolios for INGREZZA and others.Sub-event
Ingrezza is outgrowing the broader market, and IRA implementation impacts Medicare pricing.1 source
Access for Neurocrine Biosciences' INGREZZA is now tied to Medicare coverage.1 source
Keep exploring
The entities involved
-
Medicare
US federal health insurance
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.